@denovo-sh.com
上海迪诺医药科技有限公司
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Shanghai De Novo Pharmatech is an innovative biotechnology company based in the Zhangjiang High-tech Park in Shanghai, established in 2010. They are driven by science and guided by clinical needs, focusing on the development of First-in-Class and Best-in-Class pipelines. Their team consists of professionals in drug chemistry, biology, clinical translation, registration, and clinical medicine, forming a knowledgeable research and development team.
The management team brings extensive experience in new drug development and management, having previously worked for globally renowned biotechnology companies and pharmaceutical enterprises. Shanghai De Novo Pharmatech primarily focuses on two areas of early-stage research and clinical development: 1. Natural Immune Regulation: They aim to transform cold tumors, which are less responsive to existing tumor immunotherapy, into hot tumors by activating the body's natural immune system.
Their research includes selective activators for TLR8 and STING, both entering clinical development. Additionally, they are constructing the ISAC technology platform for targeted tumor microenvironment therapy. 2.
Targeted Therapy: They are developing Wee1 inhibitors and ATR inhibitors, both at the preclinical development stage, with their own intellectual property. The clinical candidate compound of ATR inhibitors shows significant advantages in efficacy and safety compared to similar molecules in clinical stages. Shanghai De Novo Pharmatech is committed to becoming a leading domestic innovative drug development enterprise, contributing to society and benefiting patients by focusing on innovative drug research and development
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online